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Sir,
Myelosuppression is frequently observed during treatment with
the multi tyrosine kinase inhibitors (TKIs) (Motzer et al, 2007;
Bhojani et al, 2008). The frequency and severity of myelosuppres-
sion varies among the drug class with sunitinib being a relative
myelotoxic compound leading to leukopenia and thrombocytope-
nia in 56–78% and 41–65% of the patients, respectively (Demetri
et al, 2006; Motzer et al, 2007).
In a previous issue of the British Journal of Cancer, Kumar et al
(2009) have investigated the potency of three TKIs that target the
vascular endothelial growth factor receptor; sunitinib, sorafenib
and pazopanib, against a large panel of kinases in in vitro and
cellular assays. They further evaluated the potential for myelo-
suppression by measuring the ability of these TKIs to inhibit
human bone marrow progenitor growth. Both c-kit and flt-3
seemed to be important kinases for the development of early
stem and progenitor cells, as determined by Kumar et al (2009).
The differences in activity against these kinases provide a plausible
explanation for the observed differences in clinical myelosuppres-
sion between sunitinib, sorafenib and pazopanib (Hartmann et al,
2009; Kumar et al, 2009).
As there is considerable variability among patients with regard
to sunitinib-induced myelosuppression, additional patient charac-
teristics could very well contribute to the development of
bone marrow toxicity. In a recent study, we have investigated
the relationship between germ-line variants in genes encoding
proteins involved in sunitinib disposition, metabolism and
mechanism of action and the development of common toxicities,
including haematological toxicities (van Erp et al, 2009). We found
a strong association between the presence of the flt-3 738C-allele,
which is a non-synonymous polymorphism in the flt-3 receptor
with currently unknown functionality, and a 2.8-fold reduction in
the risk for developing leukopenia after one cycle of sunitinib
treatment. This finding not only underlines the role of flt-3 in
myelosuppression as suggested by Kumar et al (2009) but might
also explain the large interpatient variability in sunitinib-related
leukopenia response.
In our study, only 29% of the patients developed thrombo-
cytopenia in the first treatment cycle as compared with 46% of the
patients who developed leukopenia scored according to the criteria
of Common Toxicity Criteria for Adverse Events version 3.0.
An explanation for this difference might be the high baseline
thrombocyte counts (mean: 319 10
9l
–1, range: 92–864 10
9l
–1)
in these patients. As a consequence, a larger decrease in thrombo-
cytes is necessary to develop thrombocytopenia.
We, therefore, performed a sub-analysis, in 193 patients,
in which the thrombocyte count ratios (counts after 4 weeks of
treatment/baseline counts) were univariately tested for an asso-
ciation with the flt-3 polymorphism 738T/C. The flt-3 genotype
was divided into two groups wild type (TT) (n¼59) vs C-allele
carriers (CT/CC) (n¼134) since a protective effect was observed
in C-allele carriers in developing leukopenia in our earlier analysis
(van Erp et al, 2009). In line with our previous analysis,
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Figure 1 Trombocyte counts decrease after sunitinib start in flt3 738 TT
vs CT and CC carriers. Published online 3 August 2010
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www.bjcancer.coma protective effect in thrombocyte reduction was indeed observed
for the flt-3 738C-allele carriers. After 4 weeks of sunitinib treat-
ment, the mean thrombocyte count ratios for carriers of the flt-3
738 TT genotype vs carriers of the flt-3 738 CT/CC genotype were
0.54 vs 0.65 (P¼0.024) (Figure 1).
We conclude that the flt-3 738C allele has a protective effect
against sunitinib-induced thrombocytopenia. Combined with our
earlier finding with regard to leukopenia it seems that the flt-3
738C4T polymorphism has a role in the variability of sunitinib-
induced bone marrow toxicities.
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